Federal Circuit Affirms USPTO Ruling: Prostate Cancer Combination Therapy Patent Declared Unpatentable
What would you like to do next?
Choose your path based on your current IP needs:
📋 Case Summary
| Case Name | In re: Linda Anne Snyder |
| Case Number | 23-1763 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from USPTO PTAB |
| Duration | Apr 2023 – Jul 2024 450 days |
| Outcome | Application Rejected — Unpatentable |
| Application at Issue | |
| Subject Matter | Prostate Cancer Combination Therapy |
| Accused Product | N/A – Patent Prosecution Appeal |
Case Overview
The Parties
⚖️ Applicants/Appellants
Named inventors on U.S. Patent Application No. 15/950,707, represented by Baker & Hostetler, LLP.
🛡️ Respondent/Appellee
Director of the United States Patent and Trademark Office, defending the agency’s rejection of the patent application.
The Patent Application at Issue
This case involved U.S. Patent Application No. 15/950,707 (published as US20180296574A1), covering a method or composition for a combination therapy approach targeting prostate cancer. Combination therapy patents are inherently complex to prosecute because each component may be individually known, making the non-obviousness of the combination a critical and often vulnerable claim element.
- • US15/950,707 — Combination therapy for prostate cancer
Drafting claims for a combination therapy?
Ensure your application meets patentability standards before costly prosecution.
The Verdict & Legal Analysis
Outcome
The Federal Circuit, in a per curiam ruling by Judges Prost, Clevenger, and Chen, **affirmed** the USPTO’s determination. The basis of termination is recorded as Unpatentable — meaning the applicants’ claims for a prostate cancer combination therapy were denied, and no patent rights will issue from application US15/950,707 as presented.
No damages were at issue, as this was a patent prosecution appeal rather than an infringement action. No injunctive relief was applicable.
Key Legal Issues
The verdict cause is classified as **Patentability / Invalidity-Cancellation Action**, indicating the core dispute centered on whether the claimed invention satisfied the statutory requirements for patentability under 35 U.S.C. — most likely §§ 102 (novelty), 103 (non-obviousness), or 112 (written description/enablement), which are the predominant grounds for USPTO rejection of pharmaceutical combination therapy claims.
In combination therapy patent prosecution, the most common and difficult challenge is obviousness under § 103. When each component of a therapeutic combination is individually disclosed in prior art, the USPTO and courts routinely apply the KSR International Co. v. Teleflex Inc. framework to assess whether a skilled artisan would have had motivation to combine known therapies with a reasonable expectation of success. The per curiam affirmance without detailed opinion strongly suggests the panel found the Board’s obviousness analysis — including its prior art findings and motivation-to-combine reasoning — legally sound and factually supported.
Patentability & Prosecution Strategy
This case highlights critical IP risks in biotech and pharmaceutical patent prosecution. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this prosecution outcome.
- View all related prior art in this technology space
- See which companies are most active in oncology patents
- Understand obviousness challenge patterns
🔍 Assess My Application’s Risk
Run a comprehensive patentability analysis for your combination therapy.
- Input your claims or technical features
- AI identifies potentially blocking prior art
- Get actionable obviousness risk assessment report
High Obviousness Risk
Combination therapies with known constituents
Biotech Patent Landscape
Complex prior art environment
Strong Prosecution
Requires unexpected results data
✅ Key Takeaways
Per curiam Federal Circuit affirmances signal well-settled law applied to specific facts — not new precedent, but strong confirmation of existing doctrine.
Search related case law →Combination therapy applications demand early submission of unexpected results evidence to survive § 103 challenges.
Explore prior art and evidence strategies →Frequently Asked Questions
The case involved U.S. Patent Application No. 15/950,707, published as US20180296574A1, covering a combination therapy for prostate cancer.
The court affirmed the USPTO’s determination that the claimed invention was unpatentable, consistent with the agency’s rejection on patentability grounds — most likely obviousness under 35 U.S.C. § 103.
It reinforces that combination oncology therapy claims lacking demonstrated unexpected results face significant vulnerability to USPTO rejection and Federal Circuit affirmance under established obviousness doctrine.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 23-1763
- USPTO Patent Application Search — US15/950707
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007)
- U.S. Patent and Trademark Office — Patent Resources
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.